Business Description
Bolt Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US0977021049
Share Class Description:
FRA:6LP: Ordinary SharesDescription
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.05 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.27 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -3.39 | |||||
| Beneish M-Score | -1.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 209.7 | |||||
| 3-Year EBITDA Growth Rate | -8.8 | |||||
| 3-Year EPS without NRI Growth Rate | -6 | |||||
| 3-Year FCF Growth Rate | -5.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.34 | |||||
| 9-Day RSI | 40.43 | |||||
| 14-Day RSI | 43.15 | |||||
| 6-1 Month Momentum % | 23.19 | |||||
| 12-1 Month Momentum % | -16.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.17 | |||||
| Quick Ratio | 5.17 | |||||
| Cash Ratio | 5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | 4.11 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -967.45 | |||||
| Net Margin % | -878.58 | |||||
| FCF Margin % | -885.71 | |||||
| ROE % | -48.57 | |||||
| ROA % | -36.05 | |||||
| ROIC % | -112.92 | |||||
| ROC (Joel Greenblatt) % | -290.02 | |||||
| ROCE % | -44.11 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.31 | |||||
| PB Ratio | 0.37 | |||||
| Price-to-Tangible-Book | 0.37 | |||||
| EV-to-EBIT | 0.52 | |||||
| EV-to-EBITDA | 0.54 | |||||
| EV-to-Revenue | -5.06 | |||||
| EV-to-FCF | 0.57 | |||||
| Price-to-Net-Current-Asset-Value | 0.72 | |||||
| Price-to-Net-Cash | 0.76 | |||||
| Earnings Yield (Greenblatt) % | 192.31 | |||||
| FCF Yield % | -165.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bolt Biotherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.313 | ||
| EPS (TTM) (€) | -1.697 | ||
| Beta | 0.48 | ||
| Volatility % | 43.12 | ||
| 14-Day RSI | 43.15 | ||
| 14-Day ATR (€) | 0.045797 | ||
| 20-Day SMA (€) | 1.1204 | ||
| 12-1 Month Momentum % | -16.59 | ||
| 52-Week Range (€) | 0.767 - 1.774 | ||
| Shares Outstanding (Mil) | 38.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bolt Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bolt Biotherapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bolt Biotherapeutics Inc Frequently Asked Questions
What is Bolt Biotherapeutics Inc(FRA:6LP)'s stock price today?
The current price of FRA:6LP is €1.03. The 52 week high of FRA:6LP is €1.77 and 52 week low is €0.77.
When is next earnings date of Bolt Biotherapeutics Inc(FRA:6LP)?
The next earnings date of Bolt Biotherapeutics Inc(FRA:6LP) is 2024-05-10 Est..
Does Bolt Biotherapeutics Inc(FRA:6LP) pay dividends? If so, how much?
Bolt Biotherapeutics Inc(FRA:6LP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers